Tailor-made chemotherapy based on biomarker for lung cancer and malignant mediastinal tumor

Tailor-made chemotherapy based on biomarker for lung cancer and malignant mediastinal tumor - Tailor-made chemotherapy based on biomarker

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028952

Enrollment

300

Registered

2017-09-02

Start date

2011-11-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer, malignant mediastinal tumor

Interventions

Tailor-made chemothrapy is performed for patients with advanced-stage cancer or reccurent tumor after surgery. The tailor-made chemothrapy is contined until detection of re-growth of tumors.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: advanced stage lung cancer advanced stage malignant mediastinal tumor

Exclusion criteria

Exclusion criteria: Patients not applicable for conventinal chemotherapy, due to leukocytopenia, thrombocytopenia, hepatic dysfunction, or renal dysfunction.

Design outcomes

Primary

Measure	Time frame
overall survival rate at 3 years after initial treatment	—

Secondary

Measure	Time frame
progression-free survival rate at 3 years after initial treatment response rate	—

Countries

Japan

Contacts

Public ContactCheng-long Huang

Kitano hospital Department of Thoracic Surgery

chuang@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026